Oramed Pharmaceuticals has recently transferred its POD™ oral insulin program and related assets to Lifeward in exchange for a nearly 50% stake, aligning with a commercial-stage medical technology entity to leverage its distribution and product base. Oramed retains management of the ongoing oral insulin clinical trial and holds significant equity in Alpha Tau Medical, diversifying exposure into oncology therapeutic development. The company’s latest filings reveal stable cash runway but highlight the need to secure additional financing amid ongoing operating losses and high R&D intensity typical in the biotech oral delivery sector.